Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort

BACKGROUND: Apalutamide is a potent androgen receptor (AR) antagonist that targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets. Objective: To evaluate the activity and safety of apalutamide in patients with high-risk nonmetast...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur Urol
Autori principali: Smith, Matthew R., Antonarakis, Emmanuel S., Ryan, Charles J., Berry, William R., Shore, Neal D., Liu, Glenn, Alumkal, Joshi J., Higano, Celestia S., Maneval, Edna Chow, Bandekar, Rajesh, de Boer, Carla J., Yu, Margaret K., Rathkopf, Dana E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5568792/
https://ncbi.nlm.nih.gov/pubmed/27160947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2016.04.023
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi